secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2022-12-13T23:59:59+00:00
Accession:  0000059478-22-000277
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly guides 2023 revenue $30.3B-$30.8B, EPS $7.65-$7.85; plans four new drug launches
--------------------------------------------------------------------------------

- 2023 revenue guidance $30.3B-$30.8B, up from 2022 reaffirmed $28.5B-$29.0B.
- 2023 reported EPS $7.65-$7.85; non-GAAP EPS $8.10-$8.30; 2022 reaffirmed $6.50-$6.65 reported.
- Plans to launch donanemab, mirikizumab, lebrikizumab, pirtobrutinib; potential tirzepatide obesity submission.
- Fifth consecutive 15% annual dividend increase; R&D spend $8.2B-$8.4B vs $7.1B-$7.3B 2022.
- Gross margin ~77% reported, ~79% non-GAAP; tax rate ~16%; Alimta LOE and FX headwinds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947822000277/0000059478-22-000277-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947822000277/lly-20221213.htm
  HTML page:      https://secwatch.observer/filing/0000059478-22-000277

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer